Skip to main content

Search Results

Ifosfamide

Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.

The Impossible Choice: The Role of Insurance Design on Financial Toxicity and Access to Care for Individuals with Blood Cancer

The overall goal of this project is to understand the role of insurance design on financial toxicity and access to care among individuals with blood cancer. To understand this interplay, we will use a unique and innovative linkage of the 2012-2019 Colorado Cancer Registry (CCR) to the 2013-2021 Colorado All-Payer Claims Database and the LexisNexis and TranUnion financial and life event databases.

My Myeloma Story

“What is multiple myeloma?” Those were my words after the doctor’s review of my lab results for a routine and random high blood pressure exam in November 2008.

Myeloma survivors, you've got us

Understanding Myeloma: A Quick Guide

Myeloma is a rare blood cancer

 

Blue overlay image of DNA, close-up

Is Leukemia Genetic?

Table of contents

New Study Shows 9/11 Responders Have Higher Rates of Leukemia

 

All 9/11 responders put their own lives at risk to save others from the events that occurred at the World Trade Center (WTC) on September 11, 2001, in New York City. Since then, several studies have shown elevated rates of cancers such as multiple myeloma, prostate cancer and thyroid cancer among first responders and those who worked nearby.

Impact of Insurance Type and Cost Sharing on Equity in Access to Oral Anticancer Medications for Blood Cancers

This project will evaluate the association of insurance type with insurer rejection and patient abandonment of new OAM prescriptions for blood cancers, overall and by sociodemographic factors. It will also evaluate the association of cost sharing with patient abandonment of OAM prescriptions for blood cancers and conduct simulations under alternative cost sharing scenarios to inform policy reform proposals among commercially insured enrollees.

Surviving ALL: An Intimate Look at How Cancer Affected the Careers, Relationships & Fertility of Four Young Adults

A cancer diagnosis is a devastating blow for people of all ages, but presents special challenges for young adults. This period of life is usually a time of transition as they are embarking on journeys such as school, relationships and careers. A cancer diagnosis can bring their lives to a screeching halt in the midst of these new adventures.

Birthday girl blowing out candles

Why Monthly Giving Matters

Giving regularly over time = giving patients and survivors the chance for more time.  

Monthly giving really deserves more credit—credit as a predictable, impactful funding force for our lifesaving and life-changing work. For The Leukemia & Lymphoma Society (LLS), the reliability of a regular gift helps to sustain cutting-edge research and to provide the free resources and support blood cancer patients and survivors need to live longer, better lives. 

It’s about ongoing generosity. It’s about creating a lasting impact.  

And... 

Etoposide

Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.

Woman with fruit and vegetables

Champions in myeloma research: A conversation with Urvi A. Shah, M.D. M.S.

March is Myeloma Awareness Month, and it’s also Women’s History Month. So what better time to spotlight LLS-funded women scientists who are driving discovery for myeloma patients.

In this first of my two-part series on myeloma researchers, I sat down with Urvi A. Shah, MD, MS, an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center. 

Split image of Racheli, Hodgkin lymphoma survivor. On the right, her during treatment. On the left, post-treatment.

Every Year Counts: Celebrating My Healing from Hodgkin Lymphoma

Many blood cancer survivors remember the day they were diagnosed, and they never forget it. For Racheli Alkobey Peltier—Director of Diversity, Equity, and Inclusion at The Leukemia & Lymphoma Society (LLS)— when that date comes around, it’s a chance to mark her progress.  

Each year, Racheli marks important milestones in her experience with blood cancer—taking time to reflect, feel gratitude, and look ahead. These dates are her “cancerversaries.”